CDKL1 and lung carcinoma: To elucidate the molecular mechanisms underlying the functions of CDKL1 in lung cancer, proteomic screening was previously conducted using tandem affinity purification (TAP) and mass spectrometry (MS), which revealed that the transcription factor YBX1 is a potential interacting partner of CDKL1 (Fig. 3A) [31].